05:08 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
00:11 , Nov 15, 2017 |  BC Extra  |  Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led by...
21:12 , Sep 27, 2017 |  BC Innovations  |  Emerging Company Profile

Sparing the microbiome

Eliminating disease-causing bacteria from the gut while sparing healthy commensal bacteria is one of the key challenges of creating microbiome-based therapies. Eligo Bioscience S.A.S. has a platform that couples the editing power of CRISPR with...
17:34 , Aug 31, 2017 |  BC Innovations  |  Product R&D

Cutting through resistance

Most companies employing CRISPR-Cas9 for therapeutics are using it to edit human cells, but Locus Biosciences Inc. is betting the lesser-known CRISPR-Cas3 system will do a better job of treating bacterial infections and could be...